Your browser doesn't support javascript.
loading
Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy.
Dong, Xiang; Zhang, Zewu; Zhang, Qin; Chen, Lu; Cao, Guangtai; Liu, Chen; Song, Tianqiang; Lu, Wei; Zhang, Wei.
Afiliación
  • Dong X; Department of Hepatobiliary Cancer, Research Center for Prevention and Treatment of Liver Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital. National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Hu
  • Zhang Z; Department of Hepatobiliary Surgery, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Cangzhou, Hebei, China.
  • Zhang Q; Department of Hepatobiliary Cancer, Research Center for Prevention and Treatment of Liver Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital. National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Hu
  • Chen L; Department of Hepatobiliary Cancer, Research Center for Prevention and Treatment of Liver Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital. National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Hu
  • Cao G; Department of Hepatobiliary Cancer, Research Center for Prevention and Treatment of Liver Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital. National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Hu
  • Liu C; Department of General Surgery, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Cangzhou, Hebei, China.
  • Song T; Department of Hepatobiliary Cancer, Research Center for Prevention and Treatment of Liver Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital. National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Hu
  • Lu W; Department of Hepatobiliary Cancer, Research Center for Prevention and Treatment of Liver Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital. National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Hu
  • Zhang W; Department of Hepatobiliary Cancer, Research Center for Prevention and Treatment of Liver Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital. National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Hu
J Cancer Res Clin Oncol ; 149(5): 1917-1927, 2023 May.
Article en En | MEDLINE | ID: mdl-35802197
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias del Sistema Biliar / Inhibidores de Puntos de Control Inmunológico Límite: Humans / Middle aged Idioma: En Revista: J Cancer Res Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: Hungria
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias del Sistema Biliar / Inhibidores de Puntos de Control Inmunológico Límite: Humans / Middle aged Idioma: En Revista: J Cancer Res Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: Hungria